Skip to content

Ventricular Arrhythmias in Acute Myocardial Infarction

Ventricular Arrhythmias in the Acute Phase of Myocardial Infarction: ADVERSE MI Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07517523
Acronym
ADVERSE-MI
Enrollment
500
Registered
2026-04-08
Start date
2025-06-20
Completion date
2027-10-01
Last updated
2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction (AMI), Ventricular Arrhythmia

Keywords

ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, ventricular fibrillation, ventricular tachycardia, cardiac arrest, implantable cardioverter defibrillator

Brief summary

Ventricular arrhythmias are a serious complication of myocardial infarction. The aim of this study is to provide reliable data on the management and mortality associated with ventricular arrhythmia in the setting of acute myocardial infarction.

Detailed description

Ventricular arrhythmias remain a major complication during the acute phase of myocardial infarction. The 2022 European guidelines on ventricular arrhythmias recommend implantable cardioverter-defibrillator (ICD) placement for secondary prevention when ventricular fibrillation occurs ≥ 48 hours after the infarct. Yet this recommendation rests on limited evidence. We therefore conduct a multicentre retrospective study to characterise the clinical profile, management, and prognosis of sustained ventricular arrhythmias (ventricular tachycardia and ventricular fibrillation) arising in the acute myocardial infarction setting. The primary objective of this study is to evaluate post-discharge mortality in patients who develop an arrhythmia either within 48 hours of, or more than 48 hours after, an acute myocardial infarction. Sensitivity analyses will further examine outcomes according to the arrhythmia subtype (ventricular fibrillation vs ventricular tachycardia), the presence of concomitant heart failure, and the myocardial-infarction phenotype (STEMI vs NSTEMI).

Interventions

None listed

Sponsors

Poitiers University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥ 18 years * Acute myocardial infarction * Sustained ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) at the acute phase of an acute myocardial infarction (before hospital discharge) * Between January 1, 2012 and April 14, 2024

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Post-discharge mortalitythrough study completion, an average of 2 years

Secondary

MeasureTime frameDescription
Baseline demographic and clinical characteristics at inclusionAt baselineThis outcome is the characterization of the study population at baseline, including demographic, and clinical-related variables collected at the time of myocardial infarction.
Number of participants fot each type of myocardial infarctionAt baselineIncludes revascularization strategy and other therapeutic management measures implemented during the index hospitalization.
Number of participants with each ventricular arrhythmia characteristic and management strategy during index hospitalizationAt baselineDescriptive summary of ventricular arrhythmia presentation and in-hospital management, including arrhythmia type, timing of occurrence, recurrence, and therapeutic interventions.
In-hospital mortalityFrom admission until the date of death or hospital discharge, whichever came first, assessed up to 28 daysproportion of patients who die during their hospital stay, before discharge
Number of participants with wearable cardioverter-defibrillator utilizationAt baseline
Rate of recurrent myocardial infarction after hospital dischargethrough study completion, an average of 2 years
Rate of recurrent ventricular arrhythmias after hospital dischargethrough study completion, an average of 2 years
Rate of defibrillator implantation during hospitalization and after hospital dischargethrough study completion, an average of 2 years
Number of participants, incidence, characteristics, and management of electrical stormsAt baseline

Countries

France

Contacts

CONTACTVéronique Le Marcis
veronique.le-marcis@chu-poitiers.fr+33 5 49444084
PRINCIPAL_INVESTIGATORRodrigue Garcia, MD; PhD

Cardiology department and CIC 1402; University Hospital of Poitiers

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 29, 2026